Search Technologies

Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis. The National Institute on Aging's Immunotherapeutics Unit, is seeking parties interested in licensing or co-development of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape. 

IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases.  Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop selective IL-10 and IFN-gamma peptide inhibitors.

The National Cancer Institute, Chemical Biology Laboratory is seeking parties interested in licensing NO-releasing polymers for commercial applications in wound healing.

The National Cancer Institute Laboratory of Molecular Biology seeks parties to license or co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.

This technology represents a safe yet highly efficient strategy for somatic cell reprogramming, and has broad applicability for basic research and disease modeling.

The National Cancer Institute is seeking parties interested in collaborative research to co-develop or license the in vitro and in vivo removal of targets using light energy.

The National Cancer Institute seeks partners interested in collaborative research to co-develop PARP inhibitor and NO-donor hybrid prodrugs for the treatment of cancer.

The National Cancer Institute's Medical Oncology Branch is seeking statements of capability or interest from parties interested in licensing and co-development collaborative research to further develop, evaluate, or commercialize novel kinase inhibitors targeting the PH domain of AKT.

Investigators at the National Cancer Institute have discovered fluoroquinolone derivatives as specific Tdp1 inhibitors that could potentiate the pharmacological action of Top1 inhibitors currently used in cancer treatment.